<DOC>
	<DOCNO>NCT01564810</DOCNO>
	<brief_summary>In study , investigator assess effect Cetuximab combination chemotherapy treatment unresectable metastatic colorectal cancer .</brief_summary>
	<brief_title>Cetuximab Combination With Chemotherapy Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Patients eligible inclusion primary tumor resect patient histologically confirm wild-type-KRAS colorectal adenocarcinoma synchronous liver-confined metastasis deem non-resectable . Eligible patient randomly assign chemotherapy plus cetuximab ( arm A ) chemotherapy alone ( arm B ) . Treatment plan commence 2 4 week primary surgery . Treatment continue tumor response indicate suitability surgery liver metastases disease progression unacceptable toxic effect . The primary endpoint conversion rate radical resection liver metastases，which assess local multidisciplinary team ( include three liver surgeon one radiologist ) use contrast-enhanced CT MRI 4 cycle every 2 cycle 12 cycle . To provide objective assessment change resectability , radiological image present radiologist 3 liver surgeon , blind clinical data . Patients consider resectable 50 % surgeon vote radical resection LM . For patient whose liver-metastases assess resectable , resection schedule perform within 2~3 week last treatment cycle . Following resection , patient advise continue therapeutic regimen treatment reach sum 12 cycle .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Age ≥ 18 ≤ 75 year ; 2 . Primary tumour undergone radical resection histologically confirm colorectal adenocarcinoma ; 3 . Together clinical radiological evidence first occurrence nonresectable synchronous liveronly metastases 4 . With evidence tumor EGFR expression KRAS gene wildtype status ; 5 . With one measurable tumor . 6 . Performance status ( ECOG ) 0~1 7 . A life expectancy ≥ 3 month 8 . Adequate hematological function : Neutrophils≥1.5 x109/l platelet count≥100 x109/l ; Hb ≥9g/dl ( within 1 week prior randomization ) 9 . Adequate hepatic renal function : Serum bilirubin≤1.5 x upper limit normal ( ULN ) , alkaline phosphatase ≤5x ULN , serum transaminase ( either AST ALT ) ≤ 5 x ULN ( within 1 week prior randomization ) ; 10 . Written inform consent participation trial . 1 . Previous exposure target therapy , chemotherapy , radiotherapy intervention therapy colorectal liver metastasis . 2 . Known suspected extrahepatic metastasis . 3 . Patients know hypersensitivity reaction component study treatment . 4 . Having previously participate study include possibility allocate cetuximab therapy ( whether patient actually receive cetuximab ) 5 . Clinically relevant coronary artery disease history myocardial infarction within last 12 month leave ventricular ejection fraction ( LVEF ) institutional range normal 6 . Acute subacute intestinal occlusion 7 . Pregnancy ( absence confirm serum/urine βHCG ) breastfeed 8 . Other previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma cervix 9 . Known drug abuse/ alcohol abuse 10 . Legal incapacity limit legal capacity 11 . Preexisting peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>cetuximab</keyword>
	<keyword>chemotherapy</keyword>
</DOC>